CD36 and atherosclerosis: Furthermore, butyrate treatment of Ea.hy926 cells has been found to reduce ox-LDL uptake, CD36, VCAM-1, TNF-α, and interleukin-1β/6 production while increasing IL-10 production, suggesting its potential as a treatment for atherosclerosis [50].